Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, comments on the RamuNET trial (2017-001207-68), which investigates ramucirumab and dacarbazine in patients with progressive pancreatic neuroendocrine tumors. Whilst preliminary results show an encouraging disease control rate, the primary endpoint was not reached. Adverse events were primarily gastrointestinal, infectious, and hematological. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть